Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

OBJECTIVE: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). METHODS: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were...

Descripción completa

Detalles Bibliográficos
Autores principales: Redenbaugh, Vyanka, Montalvo, Mayra, Sechi, Elia, Buciuc, Marina, Fryer, James P., McKeon, Andrew, Lennon, Vanda A., Mills, John R., Weinshenker, Brian G., Wingerchuk, Dean M., Chen, John J., Tariq Bhatti, M., Lopez Chiriboga, A. Sebastian, Pittock, Sean J., Flanagan, Eoin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637716/
https://www.ncbi.nlm.nih.gov/pubmed/34868626
http://dx.doi.org/10.1177/20552173211052656
Descripción
Sumario:OBJECTIVE: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). METHODS: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. RESULTS: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. CONCLUSIONS: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.

Ejemplares similares